Prognostic Value of GPNMB, EGFR, p-PI3K, and Ki-67 in Patients with Esophageal Squamous Cell Carcinoma.

IF 2.6 4区医学 Q3 CELL BIOLOGY

Analytical Cellular Pathology Pub Date : 2022-08-31 eCollection Date: 2022-01-01 DOI:10.1155/2022/9303081

Bo Wang, Mengyan Li, Anna Su, Yongmei Gao, Yan Shi, Chao Li, Wenying Liu, Liping Su, Wan Li, Yuqing Ma

{"title":"Prognostic Value of GPNMB, EGFR, p-PI3K, and Ki-67 in Patients with Esophageal Squamous Cell Carcinoma.","authors":"Bo Wang, Mengyan Li, Anna Su, Yongmei Gao, Yan Shi, Chao Li, Wenying Liu, Liping Su, Wan Li, Yuqing Ma","doi":"10.1155/2022/9303081","DOIUrl":null,"url":null,"abstract":"Background: GPNMB is a newly discovered tumour-promoting factor that may promote tumour cell progression by activating the PI3K/AKT pathway by EGFR. However, there are insufficient studies about GPNMB in ESCC. This study investigated the relationship between GPNMB and EGFR/PI3K pathway genes in ESCC.Methods: The expression levels of GPNMB, EGFR, p-PI3K, and Ki-67 were examined using immunohistochemistry. Statistical analysis was done by SPSS 22.0 and R.Results: GPNMB mRNA expression is higher in ESCC compared with paracancerous tissues. The expression of EGFR, PIK3CA, PIK3CB, and AKT1 was increased in GPNMB upregulated samples. GPNMB expression was positively correlated with EGFR, p-PI3K, and Ki-67 expression. GPNMB was expressed higher in the AJCC III stage, lymph node metastasis, and moderately poorly differentiated patients. EGFR was higher expressed in patients with vascular invasion; p-PI3K expression in Kazak was higher than that in Han; Ki-67 expression was higher in tumour size ≥ 3 cm. Patients with high expression of GPNMB, p-PI3K, and Ki-67 had worse OS. p-PI3K, Ki-67, nerve invasion, and lymphatic metastasis were independent risk factors, and postoperative adjuvant therapy was a protective factor in ESCC.Conclusion: As a tumour-promoting factor, GPNMB is expected to be a potential target for ESCC.","PeriodicalId":49326,"journal":{"name":"Analytical Cellular Pathology","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2022-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452951/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Analytical Cellular Pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2022/9303081","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Background: GPNMB is a newly discovered tumour-promoting factor that may promote tumour cell progression by activating the PI3K/AKT pathway by EGFR. However, there are insufficient studies about GPNMB in ESCC. This study investigated the relationship between GPNMB and EGFR/PI3K pathway genes in ESCC.

Methods: The expression levels of GPNMB, EGFR, p-PI3K, and Ki-67 were examined using immunohistochemistry. Statistical analysis was done by SPSS 22.0 and R.

Results: GPNMB mRNA expression is higher in ESCC compared with paracancerous tissues. The expression of EGFR, PIK3CA, PIK3CB, and AKT1 was increased in GPNMB upregulated samples. GPNMB expression was positively correlated with EGFR, p-PI3K, and Ki-67 expression. GPNMB was expressed higher in the AJCC III stage, lymph node metastasis, and moderately poorly differentiated patients. EGFR was higher expressed in patients with vascular invasion; p-PI3K expression in Kazak was higher than that in Han; Ki-67 expression was higher in tumour size ≥ 3 cm. Patients with high expression of GPNMB, p-PI3K, and Ki-67 had worse OS. p-PI3K, Ki-67, nerve invasion, and lymphatic metastasis were independent risk factors, and postoperative adjuvant therapy was a protective factor in ESCC.

Conclusion: As a tumour-promoting factor, GPNMB is expected to be a potential target for ESCC.

Abstract Image

查看原文本刊更多论文

GPNMB、EGFR、p-PI3K和Ki-67在食管鳞癌患者中的预后价值。

背景:GPNMB是一种新发现的肿瘤促进因子，可能通过EGFR激活PI3K/AKT通路，促进肿瘤细胞进展。然而，关于GPNMB在ESCC中的研究还不够。本研究探讨了GPNMB与ESCC中EGFR/PI3K通路基因的关系。方法:采用免疫组化方法检测GPNMB、EGFR、p-PI3K、Ki-67的表达水平。结果:GPNMB mRNA在ESCC组织中的表达高于癌旁组织。GPNMB上调后，EGFR、PIK3CA、PIK3CB、AKT1表达增加。GPNMB的表达与EGFR、p-PI3K、Ki-67的表达呈正相关。GPNMB在AJCC III期、淋巴结转移和中度低分化患者中表达较高。EGFR在血管侵犯患者中表达较高;哈萨克族p-PI3K的表达高于汉族;≥3cm的肿瘤中Ki-67表达较高。GPNMB、p-PI3K和Ki-67高表达的患者OS较差。p-PI3K、Ki-67、神经侵犯和淋巴转移是ESCC的独立危险因素，术后辅助治疗是ESCC的保护因素。结论:GPNMB作为肿瘤促进因子，有望成为ESCC的潜在靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Analytical Cellular Pathology ONCOLOGY-CELL BIOLOGY

CiteScore

4.90

自引率

3.10%

发文量

审稿时长

16 weeks

期刊介绍： Analytical Cellular Pathology is a peer-reviewed, Open Access journal that provides a forum for scientists, medical practitioners and pathologists working in the area of cellular pathology. The journal publishes original research articles, review articles, and clinical studies related to cytology, carcinogenesis, cell receptors, biomarkers, diagnostic pathology, immunopathology, and hematology.